C4 Therapeutics, Inc.
NASDAQ:CCCCBiotechnology
Healthcare
$2.48 +2.06%
+$0.08 today
- Market cap
- $325.01M
- Beta
- 2.93
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.82
52W Low $1.36High $4.60
Volume 2.75M
Average 2.76M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$98.69M
FY 2025 · Annual
Investing Cash Flow
-$8.60M
FY 2025 · Annual
Financing Cash Flow
$126.40M
FY 2025 · Annual
+178.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (83.89M) | (128.18M) | (132.49M) | (105.32M) | (104.99M) |
| Depreciation & Amortization | 1.49M | 1.68M | 1.88M | 1.82M | 1.96M |
| Deferred Income Tax | 1.88M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 21.51M | 30.02M | 27.24M | 29.66M | 19.1M |
| Change in Working Capital | (30.09M) | (16.78M) | (6.94M) | 7.65M | (29.28M) |
| Accounts Receivables | (1.23M) | 4.24M | (10.33M) | 8.7M | 701K |
| Inventory | (2.63M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.18M) | (3.33M) | 273K | (119K) | (468K) |
| Other Working Capital | (25.05M) | (17.69M) | 3.12M | (930K) | (29.52M) |
| Other Non-Cash Items | 2.13M | 7.32M | 3.48M | 1.03M | 14.52M |
| Operating Cash Flow | (86.97M) | (105.94M) | (106.84M) | (65.16M) | (98.69M) |
| Capital Expenditures | (1.28M) | (5.5M) | (1.71M) | (180K) | (607K) |
| Acquisitions (Net) | 188.06M | (63.92M) | 0 | 0 | 0 |
| Purchases of Investments | (537.74M) | (219.53M) | (129.9M) | (284.32M) | (227.07M) |
| Sales of Investments | 349.68M | 283.45M | 289.96M | 233.23M | 219.08M |
| Other Investing Activities | (188.06M) | 63.92M | 0 | 0 | 0 |
| Investing Cash Flow | (189.34M) | 58.42M | 158.35M | (51.27M) | (8.6M) |
| Debt Repayment | 0 | 0 | (12.5M) | 0 | 0 |
| Common Stock Issued | 169.47M | 777K | 57.67M | 44.37M | 126.32M |
| Common Stock Repurchased | 0 | 0 | (110K) | (194K) | (193K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.94M | 370K | 426K | 1.16M | 274K |
| Financing Cash Flow | 171.4M | 1.15M | 45.49M | 45.34M | 126.4M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (104.9M) | (46.37M) | 97M | (71.09M) | 19.1M |
| Free Cash Flow | (88.24M) | (111.44M) | (108.55M) | (65.34M) | (99.3M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$105.0M
+ D&A$2.0M
+ Stock-Based Comp$19.1M
+ Deferred Tax$0
- Working Capital-$29.3M
+ Other Non-Cash$14.5M
= Operating Cash Flow-$98.7M
- Capex-$607.0K
= Free Cash Flow-$99.3M
Analysis
FY2025 free cash flow is -$99.3M. FCF conversion is 94.6% of net income. Operating cash flow was -$98.7M, with capex of -$607.0K. The largest bridge item is Working Capital at -$29.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 |
Does CCCC generate free cash flow?
C4 Therapeutics, Inc. (CCCC) generated -$99.30M of free cash flow in fiscal 2025.
How much operating cash flow does CCCC produce?
Operating cash flow was -$98.69M, before capital expenditures of $607,000.00.
Continue the stock analysis
Jump to another research area for this company.